Filing Flows › Innoviva (INVA) › Guidance & outlook
Innoviva (INVA) guidance and outlook
Innoviva (INVA) raised its guidance on Nov 4, 2026: Revenue (segment) $43.3M for FY2026. Innoviva's 10-Q filed Nov 4, 2026 makes 6 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $43.3M | raised |
From the earnings release filed Nov 4, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 4, 2026
- All statements contained herein, other than statements of historical fact, including, without limitation, statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, intentions, expectations, goals and objectives may be forward‑looking statements.
- Our wholly owned, critical care and infectious disease operating platform with a hospital focus, is anchored by a portfolio of four commercial and marketed products, as well as an FDA-approved product which is expected to be available to patients before the end of 2026:
- Since inception, and through the end of the third quarter, the Company has repurchased 3,829,116 shares for $82.7 million, reflecting the Company’s continued confidence in its intrinsic value and long-term outlook.
- Although we have no further milestone payment obligations to GSK pursuant to the LABA Collaboration Agreement, we continue to have ongoing commercialization activities under the LABA Collaboration Agreement, including participation in the joint steering committee that are expected to continue over the life of the agreement.
- As of September 30, 2026, our total inventory included the remaining net fair value adjustments resulting from the acquisition of La Jolla of approximately $1.1 million, which will be recognized as cost of products sold when sales occur in future periods.
- If our current operating plans and financial forecasts change, we may require additional funding sooner in the form of public or private equity offerings or debt financings.
Innoviva's latest quarter
Innoviva, Q3 2026: revenue $106M (-2% year over year), operating margin 39.7%, net loss $73.9M, operating cash flow $41.7M. The chart follows the revenue to costs, profit and cash.
Questions
Did Innoviva raise or lower its guidance?
Innoviva (INVA) raised its guidance on Nov 4, 2026: Revenue (segment) $43.3M for FY2026.
What does Innoviva expect?
All statements contained herein, other than statements of historical fact, including, without limitation, statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, intentions, expectations, goals and objectives may be forward‑looking statements. Our wholly owned, critical care and infectious disease operating platform with a hospital focus, is anchored by a portfolio of four commercial and marketed products, as well as an FDA-approved product which is expected to be available to patients before the end of 2026: Since inc
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.